Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

  1. Muñoz, D.
  2. Escartín, A.
  3. Dapena, D.
  4. Coret, F.
  5. Fernández-Uría, D.
  6. Pérez, D.
  7. Casanova, B.
  8. Guijarro-Castro, C.
  9. Munteis, E.
  10. del-Campo Amigo, M.
  11. Pego, R.
  12. Calles, C.
  13. García-Rey, C.
  14. Monsalve, N.
  15. Sánchez-Matienzo, D.
Journal:
BMC Neurology

ISSN: 1471-2377

Year of publication: 2013

Volume: 13

Type: Article

DOI: 10.1186/1471-2377-13-82 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus